Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

606
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
606
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.3K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

624
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
624

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation and Commutability Study between an LC-MS-Based Reference Measurement Procedure and Immunoassays Measuring Apolipoprotein A-I and Apolipoprotein B.

Clinical chemistry·2026
Same author

99th percentile upper reference limits of the 5th and 6th generation Elecsys<sup>®</sup> cardiac troponin T high-sensitivity assays in a single cohort of healthy blood donors.

Clinical chemistry and laboratory medicine·2026
Same author

Implementation of a one-tube flow cytometry panel for measurable residual disease detection in multiple myeloma patients in clinical routine.

Cytometry. Part B, Clinical cytometry·2025
Same author

Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Radiation-Oncology Patients: A Systematic Review and Meta-Analysis.

Vaccines·2025
Same author

High-Density Lipoprotein Predicts Intrahospital Mortality in Influenza.

Journal of clinical medicine·2024
Same author

Association of serum zinc with mineral stress in chronic kidney disease.

Clinical kidney journal·2024
Same journal

Micro- and nanoplastics as emerging clinical analytes: analytical validation, interpretive uncertainty, and laboratory actionability in human specimens.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Performance of Free Light Chain reagents in the Dutch External Quality Assessment programme over the past 14 years.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

CRISPR-Cas12a-based liquid biopsy technology: challenges in large-scale clinical application.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Diagnostic biomarkers, prognostic signatures, and therapeutic resistance: shedding light on the dual role of autophagy in glioblastoma.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Artificial intelligence in diagnostic software: validation, safety, and lifecycle challenges in Europe.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Strategies for effective occurrence Management in Resource-Limited Clinical Laboratories: Challenges and practical solutions.

Clinica chimica acta; international journal of clinical chemistry·2026
See all related articles

Related Experiment Video

Updated: Apr 23, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

Soluble ST2 in heart failure.

Benjamin Dieplinger1, Thomas Mueller1

  • 1Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Linz, Austria.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|October 1, 2014
PubMed
Summary
This summary is machine-generated.

Soluble ST2 (sST2) is a novel biomarker for heart failure (HF) management. While not diagnostic, sST2 integrates inflammation, fibrosis, and cardiac stress, offering prognostic value in HF patients.

Keywords:
Biomarker-guided therapyDiagnosisDyspneaHeart failureInflammationInterleukin-33MonitoringPrognosis

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

6.2K

Related Experiment Videos

Last Updated: Apr 23, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

6.2K

Area of Science:

  • Biochemistry
  • Cardiology
  • Molecular Biology

Background:

  • Soluble ST2 (sST2) is an emerging biomarker for heart failure (HF) management.
  • It is a member of the interleukin-1 (IL-1) receptor family, acting as a decoy receptor for IL-33.
  • Elevated sST2 levels are observed in various inflammatory and cardiac diseases.

Purpose of the Study:

  • To review the role of sST2 in heart failure (HF) management.
  • To discuss analytical considerations for sST2 measurement.
  • To explore clinical applications in HF diagnosis, prognosis, and monitoring.

Main Methods:

  • Review of existing literature on sST2 in HF.
  • Analysis of sST2's association with HF severity and outcomes.
  • Examination of serial sST2 measurements for prognostic value.

Main Results:

  • sST2 integrates inflammation, fibrosis, and cardiac stress.
  • It is included in guidelines for risk stratification in acute and chronic HF.
  • sST2 is strongly associated with HF severity and poor outcomes, though not disease-specific.

Conclusions:

  • sST2 is a valuable prognostic marker in HF, despite lacking diagnostic specificity.
  • Serial sST2 measurements show prognostic utility and potential for biomarker-directed therapy.
  • Further research into sST2's clinical applications in HF is warranted.